Boehringer Reports Positive Survodutide Phase III Data
Ingelheim am Rhein, Germany, November 9, 2026 Boehringer Ingelheim has announced positive results from its global Phase III SYNCHRONIZE-CVOT...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Ingelheim am Rhein, Germany, November 9, 2026 Boehringer Ingelheim has announced positive results from its global Phase III SYNCHRONIZE-CVOT...
Plainsboro, New Jersey, USA, and Bagsværd, Denmark, November 6, 2026 Novo Nordisk has announced new real-world clinical findings showing...
Beijing, China, and Bridgewater, Massachusetts, United States, November 4, 2026 Gan & Lee Pharmaceuticals has announced positive topline results...
PLAINSBORO, New Jersey, and BAGSVÆRD, Denmark, October 29, 2026 Novo Nordisk has announced that it will present new clinical...
INDIANAPOLIS, October 28, 2026 Eli Lilly and Company has announced positive topline results from its Phase 3 TRANSCEND-T2D-2 clinical...
San Diego, California, U.S., September 22, 2026 Viking Therapeutics, Inc. has announced positive topline results from a maintenance study...
COPENHAGEN, Denmark — September 22, 2026 Zealand Pharma announced the initiation of the global registrational Phase 3a ZUPREME program...
Bagsværd, Denmark, September 21, 2026 Novo Nordisk has announced topline results from two Phase 3 trials evaluating CagriSema, an...
Caesarea, Israel, September 15, 2026 Nitinotes has announced the completion of the first EASEâ„¢ clinical trial procedures at Fondazione...
BOSTON — September 15, 2026 Syntis Bio, Inc. announced results from the 28-day multiple-ascending-dose (MAD) portion of its Phase...
